http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-107253976-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-06 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2017-06-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-03-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2020-03-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-107253976-B |
| titleOfInvention | Periplaneta americana peptide C with anti-liver cancer activity and application thereof |
| abstract | The invention provides periplaneta americana peptide C with anti-liver cancer activity and application thereof, belonging to the technical field of medicines. The periplaneta americana peptide C with anti-liver cancer activity has an amino acid sequence shown as a sequence table SEQ ID No. 1. The periplaneta americana peptide C is applied to preparation of a medicine for preventing and/or treating liver cancer. The periplaneta americana peptide C can effectively inhibit cell proliferation and migration of liver cancer cells HepG2, and the inhibition strength is increased along with the increase of the concentration of the periplaneta americana peptide C. Compared with other periplaneta americana extracts, the periplaneta americana peptide C has obvious advantages in the effect of inhibiting the proliferation of HepG 2; compared with a thalidomide positive control, the periplaneta americana peptide C has the same or better anti-liver cancer effect. The periplaneta americana peptide C provided by the invention is polypeptide, and can be conveniently and economically produced in a large scale in a manual synthesis mode, so that the limitation of the source of active substances is eliminated, and the market and production requirements can be met. |
| priorityDate | 2017-06-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 28.